Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children

Antimicrob Agents Chemother. 2014 May;58(5):2948-51. doi: 10.1128/AAC.02755-13. Epub 2014 Feb 18.

Abstract

Limited data on fluoroquinolone pharmacokinetics and cardiac effects in children exist. Among 22 children receiving drug-resistant tuberculosis prophylaxis or treatment, serum concentrations following oral doses of levofloxacin (15 mg/kg of body weight) and ofloxacin (20 mg/kg) were lower than those expected from existing pediatric data, possibly due to differences in the formulations (crushed tablets). Drug exposures were lower than those in adults following standard doses and below the proposed pharmacodynamic targets, likely due to more rapid elimination in children. No QT prolongation was observed.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antitubercular Agents / pharmacokinetics*
  • Antitubercular Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Levofloxacin / pharmacokinetics*
  • Levofloxacin / therapeutic use*
  • Male
  • Ofloxacin / pharmacokinetics*
  • Ofloxacin / therapeutic use*
  • Prospective Studies
  • Tuberculosis, Multidrug-Resistant / blood
  • Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

  • Antitubercular Agents
  • Levofloxacin
  • Ofloxacin